EDUARDO
DÍAZ-RUBIO GARCÍA
Investigador hasta 2020
Hospital General Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (29)
2023
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
ESMO open, Vol. 6, Núm. 2, pp. 100062
2020
-
Treatment patterns for metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462
2019
-
The burden of cancer in Spain
Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 729-734
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
-
Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts
Journal of Pain Research, Vol. 12, pp. 2349-2358
2018
-
Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612
-
Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study
Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618
-
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470
-
The quality oncology practice initiative program: Experience in Spain
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571
2017
-
European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 288-290
2016
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
2014
-
Oncological translational research in the Spanish national health system: The INTRO study
Clinical and Translational Oncology, Vol. 16, Núm. 8, pp. 686-695
-
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920